Why Is Penny Stock Bolt Biotherapeutics (BOLT) Up 62% Today?
I'm LongbridgeAI, I can summarize articles.Bolt Biotherapeutics (BOLT) stock surged over 60% following the announcement of a reverse merger with Prana Therapies and a $120 million private placement. The deal, structured as a stock-for-stock exchange, grants Prana shareholders 51.7% ownership while current BOLT holders retain 6.9%. Proceeds will fund the acquisition of Prana's INSPIRE platform and pipeline assets, including PRA-216. Sheila Gujrathi, Prana's founder, joins Bolt's leadership team. Wall Street maintains a 'Hold' rating on the stock.
Bolt Biotherapeutics (BOLT) stock soared 61.81% on Friday after the biotechnology company announced its acquisition of Prana Therapies alongside a private placement. Bolt Biotherapeutics noted that the acquisition was structured as a sign-and-close reverse merger. Under this, the companies will combine on a stock-for-stock basis.
The terms of the deal will have 430,746 shares of BOLT stock and 16,360.929 shares of the company's Series D non-voting convertible preferred stock exchanged for all shares of Prana Therapies. This will result in current BOLT shareholders owning 6.9% of the company, while Prana Therapies' equity holders will own 51.7% of the company. The remaining 41.4% will belong to investors of a private placement that will take place at the same time as the reverse merger.
Bolt Biotherapeutics Private Placement
As part of the merger agreement, Bolt Biotherapeutics will conduct a $120 million private placement. This money will be used to acquire 13,995.311 shares of Series D non-voting convertible preferred stock, which are convertible to 13,995,311 shares of BOLT stock. These shares will be purchased for $8,574.30 each.
The private placement also covers an additional $60 million available upon the exercise of warrants tied to the Series D non-voting convertible preferred stock. Bolt Biotherapeutics said that it expects this private placement to close on Oct. 26, 2026. The company said it plans for the preferred stock to immediately convert and the warrants to be exercised afterward.
What Will Bolt Biotherapeutics Do After the Merger?
Once the merger is complete, Bolt Biotherapeutics intends to focus on the development of Prana Therapies' pipeline. That includes its proprietary INSPIRE platform. This is led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. There's also plans for a Phase 2 study using PRA-216 in eosinophilic esophagitis (EoE).
When the deal is complete, Sheila Gujrathi will join Bolt Biotherapeutics' leadership team as its chief strategy officer. She will also become a member of its board. Gujrathi is the founder of Prana Therapies and its former CEO.
Is Bolt Biotherapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Bolt Biotherapeutics is Hold, based on a single Hold rating over the past three months. This Hold rating comes from five-star JonesTrading analyst Boris Peaker. The analyst doesn't offer a price target for BOLT stock. (See BOLT Stock Forecast)